Matches in Wikidata for { <http://www.wikidata.org/entity/Q64220737> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q64220737 description "clinical trial" @default.
- Q64220737 description "ensayu clínicu" @default.
- Q64220737 description "klinisch onderzoek" @default.
- Q64220737 description "клінічне випробування" @default.
- Q64220737 description "կլինիկական փորձարկում" @default.
- Q64220737 name "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)" @default.
- Q64220737 type Item @default.
- Q64220737 label "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)" @default.
- Q64220737 prefLabel "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)" @default.
- Q64220737 P1050 Q64220737-B72D8F36-1972-42E1-975D-4FA58D911ADF @default.
- Q64220737 P1050 Q64220737-F589115B-5C20-4718-B160-D65258BDB3A5 @default.
- Q64220737 P1132 Q64220737-62AA21FC-DB8A-4E58-804E-2154E5E4FFD7 @default.
- Q64220737 P1476 Q64220737-2A0D409F-5994-44E5-ACFD-1E849913F0EE @default.
- Q64220737 P2899 Q64220737-9E53880B-B9EF-4102-B147-00C8E4857723 @default.
- Q64220737 P3098 Q64220737-4AB0B25B-986D-4F90-BD43-4A17026F8EEE @default.
- Q64220737 P31 Q64220737-2B78B1AB-3889-4167-AEA8-7F47A0052DF8 @default.
- Q64220737 P4844 Q64220737-BD32D49D-5BB9-4BF1-BF74-C1F80F40FCD8 @default.
- Q64220737 P4844 Q64220737-D536FFE8-F11F-4914-970F-60138C46066D @default.
- Q64220737 P580 Q64220737-416EA121-6371-4D9C-B387-FF4A0B958048 @default.
- Q64220737 P582 Q64220737-4328AC8B-09DA-4C1D-9B35-55FDDC348DDC @default.
- Q64220737 P6099 Q64220737-192F40B9-8F09-41B2-977F-5A0FC26D5617 @default.
- Q64220737 P6099 Q64220737-DCBE49DD-74EC-4D1D-9802-FD1654F541CF @default.
- Q64220737 P8363 Q64220737-DA9CADAE-9DF4-4DE2-9935-EE69084E888B @default.
- Q64220737 P1050 Q180614 @default.
- Q64220737 P1050 Q33525 @default.
- Q64220737 P1132 "+293" @default.
- Q64220737 P1476 "A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)" @default.
- Q64220737 P2899 "+18" @default.
- Q64220737 P3098 "NCT02089685" @default.
- Q64220737 P31 Q30612 @default.
- Q64220737 P4844 Q13896859 @default.
- Q64220737 P4844 Q20817235 @default.
- Q64220737 P580 "2014-03-17T00:00:00Z" @default.
- Q64220737 P582 "2020-06-17T00:00:00Z" @default.
- Q64220737 P6099 Q42824440 @default.
- Q64220737 P6099 Q5452194 @default.
- Q64220737 P8363 Q78089383 @default.